Marta Palomo

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3957297/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Distinctive Biomarker Features in the Endotheliopathy of COVID-19 and Septic Syndromes. Shock, 2022, 57, 95-105.	2.1	43
2	Is the Endothelium the Missing Link in the Pathophysiology and Treatment of COVID-19 Complications?. Cardiovascular Drugs and Therapy, 2022, 36, 547-560.	2.6	37
3	The Interplay between Pathophysiological Pathways in Early-Onset Severe Preeclampsia Unveiled by Metabolomics. Life, 2022, 12, 86.	2.4	6
4	An endothelial proinflammatory phenotype precedes the development of the engraftment syndrome after autologous Hct. Bone Marrow Transplantation, 2022, 57, 721-728.	2.4	2
5	Differences and similarities in endothelial and angiogenic profiles of preeclampsia and COVID-19 in pregnancy. American Journal of Obstetrics and Gynecology, 2022, 227, 277.e1-277.e16.	1.3	23
6	Complement Mediated Endothelial Damage in Thrombotic Microangiopathies. Frontiers in Medicine, 2022, 9, 811504.	2.6	11
7	MO241: Nets and Terminal Complement Pathway as Potential Biomarkers for Complement Overactivation Assessment in Anca-Associated Vasculitis. Nephrology Dialysis Transplantation, 2022, 37, .	0.7	0
8	Endothelial damage and dysfunction in acute graft-versus-host disease. Haematologica, 2021, 106, 2147-2160.	3.5	26
9	Complement as the enabler of carfilzomibâ€induced thrombotic microangiopathy. British Journal of Haematology, 2021, 193, 181-187.	2.5	20
10	Apixaban Downregulates Endothelial Inflammatory and Prothrombotic Phenotype in an In Vitro Model of Endothelial Dysfunction in Uremia. Cardiovascular Drugs and Therapy, 2021, 35, 521-532.	2.6	15
11	Diagnostic challenges in von Willebrand disease. Report of two cases with emphasis on multimeric and molecular analysis. Platelets, 2021, 32, 697-700.	2.3	1
12	Complement and coagulation cascades activation is the main pathophysiological pathway in early-onset severe preeclampsia revealed by maternal proteomics. Scientific Reports, 2021, 11, 3048.	3.3	25
13	Enforced sialyl‣ewisâ€X (sLeX) display in Eâ€selectin ligands by exofucosylation is dispensable for CD19â€CAR Tâ€cell activity and bone marrow homing. Clinical and Translational Medicine, 2021, 11, e280.	4.0	11
14	Progressive endothelial cell damage in correlation with sepsis severity. Defibrotide as a contender. Journal of Thrombosis and Haemostasis, 2021, 19, 1948-1958.	3.8	12
15	Defibrotide: potential for treating endothelial dysfunction related to viral and post-infectious syndromes. Expert Opinion on Therapeutic Targets, 2021, 25, 423-433.	3.4	6
16	The importance of endothelial protection: the emerging role of defibrotide in reversing endothelial injury and its sequelae. Bone Marrow Transplantation, 2021, 56, 2889-2896.	2.4	8
17	Thrombotic microangiopathies assessment: mind the complement. CKJ: Clinical Kidney Journal, 2021, 14, 1055-1066.	2.9	14
18	P.149: Extracellular Vesicles From Patients With Diabetic Nephropathy Induce Endothelial Dysfunction	1.0	0

Marta Palomo

#	Article	IF	CITATIONS
19	Internalization of microparticles by platelets is partially mediated by toll-like receptor 4 and enhances platelet thrombogenicity. Atherosclerosis, 2020, 294, 17-24.	0.8	16
20	Upâ€regulation of HDACs, a harbinger of uraemic endothelial dysfunction, is prevented by defibrotide. Journal of Cellular and Molecular Medicine, 2020, 24, 1713-1723.	3.6	18
21	Hyperhemolytic Transfusion Reaction in Non-Hemoglobinopathy Patients and Terminal Complement Pathway Activation: Case Series and Review of the Literature. Transfusion Medicine Reviews, 2020, 34, 172-177.	2.0	4
22	Response to Maccio et al, "Multifactorial pathogenesis of COVIDâ€19â€related coagulopathy: Can defibrotide have a role in the early phases of coagulation disorders?â€r Journal of Thrombosis and Haemostasis, 2020, 18, 3111-3113.	3.8	10
23	The induction strategies administered in the treatment of multiple myeloma exhibit a deleterious effect on the endothelium. Bone Marrow Transplantation, 2020, 55, 2270-2278.	2.4	9
24	Defibrotide inhibits donor leucocyteâ€endothelial interactions and protects against acute graftâ€versusâ€host disease. Journal of Cellular and Molecular Medicine, 2020, 24, 8031-8044.	3.6	23
25	Endothelial Damage, Inflammation and Immunity in Chronic Kidney Disease. Toxins, 2020, 12, 361.	3.4	43
26	Is sickle cell disease-related neurotoxicity a systemic endotheliopathy?. Hematology/ Oncology and Stem Cell Therapy, 2020, 13, 111-115.	0.9	1
27	Vascular endothelial syndromes after HCT: 2020 update. Bone Marrow Transplantation, 2020, 55, 1885-1887.	2.4	17
28	Circulating Biomarkers of COVID-19-Triggered Endotheliopathy: From Conjecture to Certainty. Blood, 2020, 136, 31-32.	1.4	4
29	The avoidance of G-CSF and the addition of prophylactic corticosteroids after autologous stem cell transplantation for multiple myeloma patients appeal for the at-home setting to reduce readmission for neutropenic fever. PLoS ONE, 2020, 15, e0241778.	2.5	5
30	Defibrotide for the Treatment of Endotheliitis Complicating Sars-Cov-2 Infection: Rationale and Ongoing Studies As Part of the International Defacovid Study Group. Blood, 2020, 136, 6-8.	1.4	1
31	FO043ENDOTHELIAL DAMAGE IN CHRONIC KIDNEY DISEASE IS MEDIATED THROUGH HISTONE DEACETYLASE UPREGULATION AND CAN BE PREVENTED BY DEFIBROTIDE. Nephrology Dialysis Transplantation, 2019, 34, .	0.7	Ο
32	Complement Activation and Thrombotic Microangiopathies. Clinical Journal of the American Society of Nephrology: CJASN, 2019, 14, 1719-1732.	4.5	57
33	Acute Graft-vsHost Disease-Associated Endothelial Activation in vitro Is Prevented by Defibrotide. Frontiers in Immunology, 2019, 10, 2339.	4.8	31
34	Endothelial Dysfunction in Hematopoietic Cell Transplantation. Clinical Hematology International, 2019, 1, 45.	1.7	19
35	Innovative strategies minimize engraftment syndrome in multiple myeloma patients with novel induction therapy following autologous hematopoietic stem cell transplantation. Bone Marrow Transplantation, 2018, 53, 1541-1547.	2.4	20
36	Translational evidence of prothrombotic and inflammatory endothelial damage in Cushing syndrome after remission. Clinical Endocrinology, 2018, 88, 415-424.	2.4	14

Marta Palomo

#	Article	IF	CITATIONS
37	Antioxidant and Anti-Inflammatory Strategies Based on the Potentiation of Glutathione Peroxidase Activity Prevent Endothelial Dysfunction in Chronic Kidney Disease. Cellular Physiology and Biochemistry, 2018, 51, 1287-1300.	1.6	43
38	Endothelial damage is aggravated in acute GvHD and could predict its development. Bone Marrow Transplantation, 2017, 52, 1317-1325.	2.4	52
39	What is going on between defibrotide and endothelial cells? Snapshots reveal the hot spots of their romance. Blood, 2016, 127, 1719-1727.	1.4	59
40	Evidence of Defibrotide Internalization and Its Protective Effect in a Hepatic Endothelial in Vitro model. Blood, 2014, 124, 5960-5960.	1.4	0
41	Distinct Deleterious Effects of Cyclosporine and Tacrolimus and Combined Tacrolimus–Sirolimus on Endothelial Cells: Protective Effect of Defibrotide. Biology of Blood and Marrow Transplantation, 2013, 19, 1439-1445.	2.0	73
42	NFκB in the Development of Endothelial Activation and Damage in Uremia: An In Vitro Approach. PLoS ONE, 2012, 7, e43374.	2.5	35
43	Defibrotide Prevents the Activation of Macrovascular and Microvascular Endothelia Caused by Soluble Factors Released to Blood by Autologous Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2011, 17, 497-506.	2.0	66
44	Endothelin-1 levels predict endothelial progenitor cell mobilization after acute myocardial infarction. Microvascular Research, 2011, 82, 177-181.	2.5	16
45	Translational evidence of endothelial damage in obese individuals: inflammatory and prothrombotic responses. Journal of Thrombosis and Haemostasis, 2011, 9, 1236-1245.	3.8	40
46	Impact of Different Immunosuppresive Drugs on the Endothelium. Protective Effect of Defibrotide. Blood, 2011, 118, 5319-5319.	1.4	3
47	Proofâ€ofâ€concept trial on the efficacy of sodium tungstate in human obesity. Diabetes, Obesity and Metabolism, 2010, 12, 1013-1018.	4.4	26
48	Endothelial Dysfunction after Hematopoietic Stem Cell Transplantation: Role of the Conditioning Regimen andAthe Type of Transplantation. Biology of Blood and Marrow Transplantation, 2010, 16, 985-993.	2.0	109
49	The Release of Soluble Factors Contributing to Endothelial Activation and Damage after Hematopoietic Stem Cell Transplantation Is Not Limited to the Allogeneic Setting and Involves Several Pathogenic Mechanisms. Biology of Blood and Marrow Transplantation, 2009, 15, 537-546.	2.0	66
50	Quantitative and qualitative analysis of proteins in fresh frozen plasma obtained from whole blood donations and prepared with two photochemical treatments. Transfusion and Apheresis Science, 2008, 39, 115-121.	1.0	17
51	Inhibition of tyrosine kinase activity prevents the adhesive and cohesive properties of platelets and the expression of procoagulant activity in response to collagen. Thrombosis Research, 2008, 121, 873-883.	1.7	7
52	Apigenin Inhibits Platelet Adhesion and Thrombus Formation and Synergizes with Aspirin in the Suppression of the Arachidonic Acid Pathway. Journal of Agricultural and Food Chemistry, 2008, 56, 2970-2976.	5.2	74
53	Effect of Two Different Dialysis Membranes on Leukocyte Adhesion and Aggregation. Nephron Clinical Practice, 2007, 106, c1-c8.	2.3	7
54	Endothelial Dysfunction in Autologous Hematopoietic Stem Cell Transplantation Blood, 2007, 110, 4855-4855.	1.4	0

#	Article	IF	CITATIONS
55	Alterations of ADAMTS-13 Activity as a Common Indicator of the Endothelial Dysfunction Developing in Different Thrombotic Microangiopathies Blood, 2006, 108, 4091-4091.	1.4	0